Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The biochemistry part in the diagnosis of chylothorax and chyle effusion

Autor: Gres, P., Lefrere, B., Sakka, M., Coiffard, J., Zenati, B., Guilbert, Z., Audon, T., Cherfils, C., Fesel-Fouquier, V., Bittar, R., Bonnefont-Rousselot, D.

Publikováno v: In Atherosclerosis August 2022 355

Combinatorial, additive and dose-dependent drug-microbiome associations

Autor: Forslund, SK, Chakaroun, R, Zimmermann-Kogadeeva, M, Markó, L, Aron-Wisnewsky, J, Nielsen, T, Moitinho-Silva, L, Schmidt, TSB, Falony, G, Vieira-Silva, S, Adriouch, S, Alves, RJ, Assmann, K, Bastard, J-P, Birkner, T, Caesar, R, Chilloux, J, Coelho, LP, Fezeu, L, Galleron, N, Helft, G, Isnard, R, Ji, B, Kuhn, M, Le Chatelier, E, Myridakis, A, Olsson, L, Pons, N, Prifti, E, Quinquis, B, Roume, H, Salem, J-E, Sokolovska, N, Tremaroli, V, Valles-Colomer, M, Lewinter, C, Søndertoft, NB, Pedersen, HK, Hansen, TH, Amouyal, C, Andersson Galijatovic, EA, Andreelli, F, Barthelemy, O, Batisse, J-P, Belda, E, Berland, M, Bittar, R, Blottière, H, Bosquet, F, Boubrit, R, Bourron, O, Camus, M, Cassuto, D, Ciangura, C, Collet, J-P, Dao, M-C, Djebbar, M, Doré, A, Engelbrechtsen, L, Fellahi, S, Fromentin, S, Galan, P, Gauguier, D, Giral, P, Hartemann, A, Hartmann, B, Holst, JJ, Hornbak, M, Hoyles, L, Hulot, J-S, Jaqueminet, S, Jørgensen, NR, Julienne, H, Justesen, J, Kammer, J, Krarup, N, Kerneis, M, Khemis, J, Kozlowski, R, Lejard, V, Levenez, F, Lucas-Martini, L, Massey, R, Martinez-Gili, L, Maziers, N, Medina-Stamminger, J, Montalescot, G, Moute, S, Neves, AL, Olanipekun, M, Le Pavin, LP, Poitou, C, Pousset, F, Pouzoulet, L, Rodriguez-Martinez, A, Rouault, C, Silvain, J, Svendstrup, M, Swartz, T, Vanduyvenboden, T, Vatier, C, Walther, S, Gøtze, JP, Køber, L, Vestergaard, H, Hansen, T, Zucker, J-D, Hercberg, S, Oppert, J-M, Letunic, I, Nielsen, J, Bäckhed, F, Ehrlich, SD, Dumas, M-E, Raes, J, Pedersen, O, Clément, K, Stumvoll, M, Bork, P, The MetaCardis Consortium (Hoyles, L.)

Publikováno v: Nature
Nature, 2021, 600 (7889), pp.500-505. ⟨10.1038/s41586-021-04177-9⟩

During the transition from a healthy state to cardiometabolic disease, patients become heavily medicated, which leads to an increasingly aberrant gut microbiome and serum metabolome, and complicates biomarker discovery1-5. Here, through integrated mu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d63d45a4e7d6e8c270f49c7d2bf0ce1
http://edoc.mdc-berlin.de/21160/1/21160oa.pdf

Apport de la RMN dans l’évaluation du risque cardiovasculaire lié aux dyslipidémies

Autor: Bonnefont-Rousselot, D., Bittar, R., Atassi, M., Bruckert, E., Chapman, M.J.

Publikováno v: In Annales Pharmaceutiques Francaises 2008 66(3):123-128

Lipoprotein-associated phospholipase A2 activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia

Autor: Mattina, A, Rosenbaum, D, Bittar, R, Bonnefont-Rousselot, D, Noto, D, Averna, M, Bruckert, ., Giral, P

Background and Aim: Lipoprotein-associated phospholipase A2(Lp-PLA2) plays a key role in atherosclerosis development. It is considered a marker of increased risk of cardiovascular disease (CVD) and plaque vulnerability. Familial hypercholesterolemia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3658::7b4390acef7059c51f7daa78e2dc6420
http://hdl.handle.net/10447/281979